Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

UltraSound Guided Distal Radial Artery vS Conventional Transradial Access for Interventional Coronary Angiography (US-DRASTIC)

24 de maio de 2026 atualizado por: Grigorios Tsigkas, University Hospital of Patras
Comparative study of ultrasound-guided distal radial access versus conventional radial access regarding the incidence of vascular access crossover.

Visão geral do estudo

Descrição detalhada

Current European and American guidelines issued by the European Society of Cardiology (ESC), the American Heart Association (AHA), and the Society for Cardiovascular Angiography and Interventions (SCAI) recommend transradial access (TRA) as the preferred access route for cardiac catheterization in both acute and chronic coronary syndromes, as well as in complex coronary interventions. Compared with transfemoral access, transradial access has demonstrated significant benefits regarding vascular complications, major bleeding, mortality, and earlier mobilization and discharge of patients.

In recent years, access through the distal segment of the radial artery in the anatomical snuffbox has emerged as a technique with highly beneficial characteristics comparable to conventional radial access, while also offering additional advantages. The ANGIE study demonstrated that distal radial access was associated with a statistically significant reduction in radial artery occlusion compared with conventional radial puncture. Puncture of the distal radial artery preserves antegrade blood flow in the forearm during hemostatic compression, thereby reducing the risk of arterial occlusion.

Existing literature Although the benefit of distal radial access in preventing radial artery occlusion has now been established, the same does not apply to crossover incidence, namely the need to change to an alternative vascular access site because the intervention cannot be completed through the initially selected access.

Several studies have shown higher crossover rates with distal radial access compared with conventional radial access. In the study by Koutouzis et al., distal radial access failed more often, with a crossover incidence of 30% versus 2% in the conventional radial group. Similar findings were reported in the DAPRAO study, the ANGIE trial, the DISCO RADIAL trial, the CONDITION trial, and observational studies and meta-analyses. Overall, published evidence consistently suggests that distal radial access is associated with a higher likelihood of crossover than conventional radial access when performed without ultrasound guidance.

Aim and originality of the study A common characteristic of all the above studies is that the comparison between the two access techniques was performed using anatomical guidance rather than ultrasound guidance.

As noted in the SCAI recommendations, failure to catheterize the radial artery is the leading cause of transradial procedural failure. The radial artery is relatively small in diameter, may be calcified, or may present anatomical variations that complicate vascular access. Two-dimensional ultrasound may therefore be a valuable tool for pre-procedural planning and real-time guidance.

A large meta-analysis of 12 studies including 2,432 adults undergoing conventional transradial access under ultrasound guidance showed improved first-pass success rates and reduced access failure rates. Similarly, ultrasound-guided distal radial access significantly increased successful intervention rates in the study by Mori et al. Consequently, the purpose of the present study is to demonstrate ultrasound guidance as a technique capable of increasing successful completion rates for both vascular approaches, while establishing distal radial access as a non-inferior alternative to conventional radial access regarding crossover probability.

Methodology The study will be conducted after approval by the Scientific Council and the Ethics and Deontology Committee of the University General Hospital of Patras.

This is a prospective, randomized, single-center, non-inferiority clinical study that will be carried out in the Hemodynamic Laboratory of the Cardiology Department of the University General Hospital of Patras in collaboration with the Radiology Department.

Study population The control group will undergo coronary angiography through conventional transradial access (TRA). The intervention group will undergo coronary angiography through distal radial access (DRA). Radial artery puncture will be performed exclusively under ultrasound guidance. Patients meeting the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to DRA or TRA.

Arterial access procedure:

The procedure begins with sterilization of both potential puncture sites regardless of randomization group. Conventional radial artery puncture is performed approximately 2-3 cm proximal to the styloid process. In patients randomized to distal transradial access (dTRA), puncture is performed more distally in the anatomical snuffbox at an angle of 30-80 degrees.

The interventional cardiologist uses the ultrasound probe exclusively, covered with a sterile protective sheath, to identify anatomical landmarks, define a safe puncture site, and avoid injury to adjacent structures. Local lidocaine infiltration is then performed under ultrasound guidance. The intravascular position of the needle is confirmed by ultrasound visualization and continuous blood flow.

After successful puncture of the radial artery, a 6 French sheath is inserted using the Seldinger technique. Subsequently, 50 IU/kg unfractionated heparin is administered (100 IU/kg total dose in case of angioplasty), together with nitroglycerin according to standard practice.

Hemostasis procedure After completion of the procedure, a TR band device is used. Hemostasis is assessed at 0,5 ,1, 2, and 3 hours after placement of the device, and if hemostasis is not achieved within this timeframe, manual compression is applied.

Data collection

For all participants, the following will be recorded:

  • Demographic characteristics, cardiovascular risk factors, medical history, and chronic medication
  • Body weight and body mass index (BMI)
  • Reason for catheterization (STEMI, NSTEMI, unstable angina, stable coronary artery disease, suspected coronary artery disease, or valvular disease)
  • Periprocedural antiplatelet or anticoagulant therapy
  • Laboratory tests: Ht, Hgb, PLT, WBC, Urea, Creatinine
  • Allen test and quality of radial artery pulse
  • Total puncture attempts and total time to achieve vascular access
  • Fluoroscopy duration, total angiography time, and contrast volume
  • Number and type of diagnostic catheters used
  • Type of hemostatic device and duration of hemostasis Primary endpoint Need for vascular access crossover due to failed puncture, failed wire or sheath advancement, or inability to complete the procedure through the initial vascular access. The exact reason for crossover will be recorded.

Secondary endpoints

  • Local hematoma classified according to EASY criteria
  • Arterial spasm severity
  • Sheath placement time
  • Total procedural time
  • Time from puncture initiation until completion of coronary angiography before PCI
  • Time required for diagnostic coronary angiography after sheath placement
  • Time required until PCI completion
  • Total fluoroscopy time
  • Total DAP
  • Air Kerma
  • Hemostasis duration
  • Vascular complications (arterial perforation, pseudoaneurysm, arteriovenous fistula)
  • Distal radial artery occlusion before discharge
  • Bleeding events according to BARC classification

Tipo de estudo

Intervencional

Inscrição (Estimado)

1400

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Athinagoras Theofilatos
  • Número de telefone: +30 6946747300
  • E-mail: athinag@gmail.com

Estude backup de contato

  • Nome: Grigorios Tsigas, assistant professor
  • Número de telefone: +30 6974466662

Locais de estudo

      • Pátrai, Grécia
        • Recrutamento
        • University Hospital of Patras
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Indication for Invasive coronary angiography

Exclusion Criteria:

  • STEMI
  • Renal replacement therapy patients
  • Serious dermal or bone deformity of the radiocarpal joint
  • Shock

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: ultrasound guided distal radial artery
ultrasound guided distal radial artery acess for coronary angiography
Diagnostic and if indicated percutaneus coronary intervention during coronary angiography
Outros nomes:
  • pci
Comparador Ativo: ultrasound guided conventional transradial acess
ultrasound guided conventional transradial acess for coronary angiography
Diagnostic and if indicated percutaneus coronary intervention during coronary angiography
Outros nomes:
  • pci

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
crossover
Prazo: Periprocedural.Up to 5 mins will be allowed before giving up on designated method to obtain access
Need for a different access to begin the procedure other than the one specified in the patient's arm
Periprocedural.Up to 5 mins will be allowed before giving up on designated method to obtain access

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Arterial vasospasm
Prazo: periprocedural
periprocedural
hemostasis
Prazo: Will be checked at set intervals of 30-60-90-180 mins post procedure
Time from procedure's end until removal of hemostatic device
Will be checked at set intervals of 30-60-90-180 mins post procedure
Time until pci
Prazo: periprocedural
Time from first needle puncture until pci (percutaneous coronary intervention) has been completed (If needed)
periprocedural
radial artery occlusion
Prazo: 30 days post procedure
ultrasound evaluation of radial artery patency after end of hemostasis
30 days post procedure
hematoma
Prazo: pre discharge , post procedure
using EASY classification
pre discharge , post procedure
Time required for sheath insertion
Prazo: periprocedural
Time required from first puncture until sheath is sucessfully introduced into the artery
periprocedural
Total procedure time
Prazo: periprocedural
Time from first needle puncture until procedure end (hemostatic device placement signals the end )
periprocedural
Coronary angiography time
Prazo: periprocedural
Time from first needle puncture until all 3 coronary arteries have been sufficiently depicted
periprocedural

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de maio de 2026

Conclusão Primária (Estimado)

12 de maio de 2028

Conclusão do estudo (Estimado)

1 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de maio de 2026

Primeira postagem (Real)

1 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

We plan to share data with other researchers only if they're formally requested and cited afterwards

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever